IAS 2017: IAS Conference on HIV Pathogenesis, Treatment and Prevention Paris, France July 23-July 26

Conference Reports for NATAP


IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France 23-26 July 2017

	IAS 2017 Summary Report, Eric Daar - Eric S. Daar, M.D. Chief, Division of HIV Medicine Harbor-UCLA Medical Center Professor of Medicine David Geffen School of Medicine at UCLA - (09/03/17) HIV Prevention at IAS 2017 - Jared Baeten, MD PhD Connie Celum, MD MPH University of Washington (08/14/17) Metabolics at IAS 2017: bone, CVD, Comorbidities, Brain, Fatty Liver - (10/16/17) LONG-ACTING IBALIZUMAB SUSCEPTIBILITY IN MULTI-DRUG RESISTANT HIV PATIENTS - (10/12/17) Optimism and concern at IAS 2017 - Comment - (09/26/17) 2 ART Interruption Cure Studies at IAS 2017 - (09/20/17) Maviret /G-P in HIV+ Coinfected / ART DDIs - (09/12/17) IAS: Stigma, New HIV Infections Up in Key Populations, PrEP Access Disparities, Poor Adherence in Medicaid, High Comorbidities in Canada, Immunosenescence in HIV+ Kids, Health Outcomes-Women who have Sex with Women/Transgender Women-US - (09/07/17) Pharmacokinetics, pharmacodynamics and pharmacogenomics of efavirenz 400mg once-daily during pregnancy and postpartum - (09/07/17) Dolutegravir / tenofovir / emtricitabine (DTG/TDF/FTC) started in pregnancy is as safe as efavirenz / tenofovir / emtricitabine (EFV/TDF/FTC) in nationwide birth outcomes surveillance in Botswana - (09/07/17) Pharmacokinetic (PK) Modelling and Simulation to Support Weight-Based Dosing of Maraviroc (MVC) in Pediatric Subjects When Co-administered With Potent CYP3A Inhibitors - (09/07/17) Maraviroc Pharmacokinetics and Dosing Recommendations in CCR5-Tropic HIV-1-Infected Children Aged 2 to <18 Years - (09/07/17) Longer-Term Safety of Maraviroc in Pediatric Patients With R5 HIV: Follow-up Data From Study A4001031 - (09/07/17) Uptake of HLA-B*5701 Screening and Its Impact on Clinically Suspected Hypersensitivity Reaction to Abacavir in the OPERA Observational Database - (09/07/17) Inhibiting memory CD4+ T-cell self-renewal to reduce HIV persistence - (09/07/17) Atypical Mutations for RAL Resistant Clinical Isolates and Associated Integrase Strand Transfer Inhibitor Susceptibility With Public Algorithms With Public Algorithms - (09/07/17) The Effect of Fostemsavir on Methadone and The Effect of Fostemsavir on Methadone and Buprenorphine Pharmacokinetics - (09/07/17) The Effect of Fostemsavir on the Pharmacokinetics of a Combined Oral Contraceptive (OC) Containing Ethinyl Estradiol (EE) and Norethindrone (NE) in Healthy Female Subjects - (09/07/17) Pregnancy and Neonatal Outcomes following Prenatal Exposure to Dolutegravir - (09/07/17) Safety, Efficacy, and Dose-Response of GSK3532795/BMS-955176 Plus Tenofovir/Emtricitabine in Treatment-Naïve HIV-1-Infected Adults: Week 24 Primary Analysis - (09/07/17) Resistance Profile of HIV-1 Maturation Inhibitor GSK3532795 / GSK28338232 - (09/07/17) An Analysis of Neurologic and Psychiatric Adverse Events of Subjects Receiving the Investigational HIV-1 Maturation Inhibitor (MI) GSK3532795/BMS-955176 - (09/07/17) BMD After Switch to Dolutegravir+Rilpivirine - (09/07/17) IAS: How Many on PrEP in USA - Changes in Truvada® for HIV Pre-exposure Prophylaxis Utilization in the USA: 2012-2016 - Disparities - (09/07/17) Generic treatments for HIV, HBV, HCV, TB could be mass produced for < $90 per patient - (09/07/17) Barriers to uptake of pre-exposure prophylaxis among respondents to the Flash! - PrEP in Europe survey - (09/02/17) Pre-exposure prophylaxis (PrEP) among men who have sex with men (MSM) in the Netherlands: motives to choose for, switch to, or stop with daily or event-driven PrEP - (09/02/17) Self-Report and Medication Possession Ratio are Accurate Measures of HIV Pre-Exposure Prophylaxis Use in a Real-World Clinical Setting - (09/02/17) Bone Mineral Density at the Hip Declines Twice as Quickly Among HIV-Infected Women than Men - (08/14/17) PrEP at IAS 2017 / IAS Coverage: New HIV & HCV Drugs, Fatty Liver in HIV - (08/11/17) Peripheral blood and cerebrospinal fluid viremia of 24-weeks MONOtherapy of DOlutegravir in HIV-1 virologically suppressed patients: MONODO study - (08/10/17) Higher HDL, better brain? Higher HDL cholesterol is associated with better cognition in a cohort of older persons living with HIV infection - (08/10/17) Fatty Acid Profiles Altered by HIV Infection Persist Despite Suppressive Antiretroviral Therapy (ART) and are Associated with Immune Activation in the ACTG 5248 Study - (08/10/17) No HIV Infections With Generic TDF/FTC PrEP in Large London Group - Mark Mascolini (08/10/17) Beyond viral suppression: the quality of life of people living with HIV in Sweden / EATG Aging/HIV Call To Action: 'Beyond Viral Suppression' - (08/09/17) Microglial Cells That Are Latently Infected By HIV Are Activated By Inflammatory Stimuli and Induce Neuronal Damage - (08/09/17) Prevalence over time and predictive factors of HIV-associated neurocognitive disorder (HAND) in HIV-positive patients - (08/09/17) Assessing depression's impact on neurocognitive performance in the NAMACO study - (08/09/17) New HIV & HCV Drugs at IAS / Dual ARTs / Fatty Liver in HIV+ - (08/09/17) Cardiovascular Disease (CVD) and Chronic Kidney Disease (CKD) Event Rates in HIV-positive Persons at high Predicted CVD and CKD Risk: Results from the D:A:D Study - Combining Heart and Kidney Risk Scores Improves Prediction in HIV Group - Mark Mascolini (08/08/17) Health behaviors and outcomes in a U.S. cohort of transgender women in HIV care - (08/08/17) More Depression, Worse Quality of Life in Transgender Women vs Men With HIV - Mark Mascolini (08/08/17) Cerebral Small Vessel Disease Signal Similar in Older Men With vs Without HIV - Mark Mascolini (08/08/17) Inflammation and Obesity Tied to Incident Diabetes in Veterans With HIV - Mark Mascolini (08/07/17) Effects of Syringe Distribution Policy Change at A Syringe Services Program in Baltimore, MD: A Forecast Analysis - (08/07/17) Good HIV-Related Diarrhea Control With 20 to 24 Weeks of Crofelemer - Mark Mascolini (08/07/17) Only 5% DAA Failure Rate in Large French Cohort With HCV/HIV - Mark Mascolini (08/07/17) HIV Risk Factors and Associated Health Outcomes Among Sexual Minority Women in the United States - Sexual Violence, Drug Injecting, Risky Sex With Men Tied to STI Risk in US Lesbians - Mark Mascolini (08/07/17) Widening Needle Distribution Cuts New HIV Cases in Baltimore - Mark Mascolini (08/07/17) Estimating HIV incidence and the undiagnosed HIV population in the European Union/European Economic Area - Estimated 120,000 People With Undiagnosed HIV Across Europe in 2015 - Mark Mascolini (08/07/17) Safety and acceptability trial of the dapivirine vaginal ring in U.S. adolescents - Dapivirine Vaginal Ring Safe and Acceptable in US Adolescents - Mark Mascolini (08/07/17) An Open Label Multiple Dose Phase 1 Assessment of Long Acting Rilpivirine - Long-Acting Rilpivirine Suppresses Replication in Rectal Explants - Mark Mascolini (08/07/17) Half of HIV+ Medicaid Users Have Poor Adherence, Driving Up Costs - Mark Mascolini (08/07/17) Half of HIV+ Medicaid Users Have Poor Adherence, Driving Up Costs - Mark Mascolini (08/06/17) Atrial Fibrillation at an Earlier Age in People With HIV Infection - Mark Mascolini (08/06/17) HIV Linked to Decreased Erectile Function in MSM 45 or Older - comorbidities, depression, frailty - Mark Mascolini (08/06/17) Asians, Blacks, Young People Fall Short in US Viral Suppression Comparison - Mark Mascolini (08/06/17) Fatty Liver in HIV+ at IAS - (08/05/17) Mortality Benefit From DAAs Most Likely With Advanced Fibrosis in Canada - Trends in cause-specific mortality in HIV-HCV co-infected patients in Canada (2003-2016): Early impact of HCV therapy - Mark Mascolini (08/04/17) HIV Disclosure Crime Convictions Differ by Race/Gender, Gay/Straight Status in US - Mark Mascolini (08/04/17) PIs Plus Tenofovir Not Tied to Fracture in French Case-Control Study - Mark Mascolini (08/04/17) No HIV Transmissions in Gay Couples if HIV+ Partner Has Undetectable Virus - Mark Mascolini (08/04/17) Low HIV+ Cell Tally in Blood, Colon, Lymph Nodes in Earliest Infection Phase - Mark Mascolini (08/04/17) TCM CD4 T cell infection extent before ART associated with immune failure and HIV persistence on ART - (08/04/17) Successful switch to once-daily single-tablet regimen (STR) containing elvitegravir (EVG) or dolutegravir (DTG) in virologically suppressed HIV-1 infected patients despite archived resistant quasispecies - (08/04/17) COMORBIDITIES IN PATIENTS LIVING WITH HIV (PLWHIV) COMPARED TO MATCHED NON HIV CONTROLS: AN EPIDEMIOLOGICAL ANALYSIS USING A CLAIMS DATABASE IN FRANCE - (08/04/17) Switch to Dolutegravir Noninferior to Continued PI in Older Group With Heart Risk - Mark Mascolini - (08/04/17) Overweight/Obesity Rate Rises After SVR in HCV/HIV-Coinfected People - Mark Mascolini - (08/04/17) Depression, Brain Changes & cART in HIV+ / Role of basal ganglia in depression in HIV-infected individuals - (08/03/17) One-year experience with Pre-Exposure Prophylaxis (PrEP) Implementation in France with TDF/FTC - (08/03/17) Is on-demand PrEP with TDF/FTC effective among MSM with infrequent sexual intercourse? - (08/03/17) More and earlier cardiovascular events (CVE) and shorter overall survival (OS) in HIV-positive patients (HIV+) compared to the general population differ by sex - (08/03/17) Prevalence of Comorbidities and Impact of HIV and Comorbidities on Health Care Resource Utilization - (08/03/17) Potential for HIV transmission among adolescents and young adults receiving antiretroviral therapy - 'PrEP missed opportunities' - (08/03/17) Zoledronic Acid Boosts Bone Density More Than Switch From TDF - (08/03/17) Changes in Truvada® for HIV Pre-exposure Prophylaxis Utilization in the USA: 2012-2016 - Disparities - (08/02/17) Limited implementation of HIV pre-exposure prophylaxis among public health departments in North Carolina, United States - (08/02/17) Impact of microbiota on female genital tissue and plasma concentrations of dapivirine - (08/02/17) Experience of Living With HIV: Diagnosis and Disclosure - Findings From the Positive Perspectives Study - self-stigma is high, 63% of older HIV+ have 3+ Comorbidities - (08/02/17) Dolutegravir Use During Pregnancy and Birth Outcomes: Data From the Antiretroviral Pregnancy Registry (APR) - (08/02/17) Efficacy and Safety of Switching From RPV/FTC/TDF or EFV/FTC/TDF to RPV/FTC/TAF in Black Adults - (08/02/17) Efficacy and Safety of Tenofovir Alafenamide vs Tenofovir DF in HIV-Infected, Virologically Suppressed, Older Adults at Week 96: Subgroup Analysis of a Randomized Switch Study (Study 311-1089) - (08/02/17) Adults With Renal Impairment Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Have Improved Renal and Bone Safety Through 144 Weeks - (08/02/17) Factors associated with the occurrence of suicide among French people living with HIV in the HAART era: a nested case-control study in the Dat'AIDS cohort - (08/02/17) T cell immune exhaustion in gut-associated lymphoid tissue during treated primary HIV infection: Implications for HIV persistence - (08/02/17) Experiences and perceptions of PrEP among gay, MSM, and TGW in the PROUD study in England: 'Rules' of Sex, Psychological, Psychosocial Benefits - Mark Mascolini - (07/31/17) Reasons for not using PrEP in a national on-line sample of U.S. men who have sex with men (MSM) - Cost, Side Effects, Access Lead Reasons for PrEP Nonuse by US MSM - Mark Mascolini - (07/31/17) Maintenance Therapy With 400/100 mg of Darunavir/Ritonavir for 48 Weeks - Mark Mascolini - (07/31/17) Overweight/Obesity Rate Rises After SVR in HCV/HIV-Coinfected People - Mark Mascolini (07/31/17) Early initiation of antiretroviral treatment post SIV infection does not resolve lymphoid tissue activation - (07/31/17) HIV-1 DNA ultra-deep sequencing analysis at initiation of the dual-therapy DTG+3TC in the maintenance DOLULAM pilot study - (07/31/17) Adherence intentions, long-term adherence and HIV acquisition among PrEP users in the PROUD open-label randomised control trial of PrEP in England (07/31/17) Long term follow up of PROUD Evidence for high continued HIV exposure and durable effectiveness of PrEP - (07/31/17) HIV mediated immunosenescence in young adults infected at birth [and HIV+ adults too despite undetectable VL] - (07/31/17) Prolonged HIV-1 Remission in an Individual Treated During Hyperacute Infection - (07/31/17) Evidence of production of HIV-1 proteins from "defective" HIV-1 proviruses in vivo: Implication for persistent immune activation and HIV-1 pathogenesis - (07/31/17) ACTG A5353: A pilot study of dolutegravir (DTG) + lamivudine (3TC) for initial treatment of HIV-1-infected participants with HIV-1 RNA <500,000 copies/ml - (07/31/17) ABX464 decreases total HIV DNA in PBMC's when administered during 28 days to HIV-infected patients who are virologically suppressed - (07/28/17) New HIV Down in US MSM in 2008-2014, But Up in Hispanics, Younger Men - Mark Mascolini (07/28/17) Is on-demand PrEP a suitable tool for MSM who practice chemsex? Results from a sub-study of the ANRS-IPERGAY trial - Chemsex Users in IPERGAY Twice as Likely to Use As-Needed PrEP - Mark Mascolini (07/28/17) Evaluation of the risk of birth defects among children exposed to raltegravir in utero in the ANRS-French Perinatal Cohort EPF - Raltegravir Not Tied to Birth Defects in French Study of 479 Births - Mark Mascolini (07/28/17) Heightened Risk of Peripheral Arterial Disease With HIV in Veterans (07/27/17) Maintenance With Raltegravir/Etravirine Strong at 48 Weeks in Older Adults - Efficacy of a Maintenance Strategy with Raltegravir/Etravirine : the ANRS 163 ETRAL trial - Mark Mascolini (07/27/17) CDC Transmission Study Puts Hispanic MSM at Leading Edge of HIV Spread - Analysis of U.S. HIV sequence data indicates that recent and rapid HIV transmission is focused among young Hispanic/Latino men who have sex with men - Mark Mascolini (07/27/17) No HIV Transmissions in Gay Couples if HIV+ Partner Has Undetectable Virus - Mark Mascolini (07/27/17) Impact of risk perception trajectory on PrEP and condom use among Men who have Sex with Men during the Open-Label-Extension of the ANRS-IPERGAY trial - (07/27/17) Slowing the premature aging process: the benefits of viral control and smoking cessation on telomere length - (07/27/17) Phase 3 Randomized, Controlled, Clinical Trial of Bictegravir Coformulated With FTC/TAF in a Fixed-Dose Combination vs Dolutegravir + FTC/TAF in Treatment-Naïve HIV-1-Positive Adults: Week 48 Results - (07/27/17) Impact of exposure to each antiretroviral treatment (ARV) on the risk of fracture in HIV-infected individuals - (07/27/17) Sub-Study 202094 of SWORD-1 and SWORD-2: Switch From TDF-Containing Regimen to DTG + RPV Improves Bone Mineral Density and Bone Turnover Markers Over 48 Weeks - (07/26/17) Single Doses as Low as 0.5 mg of the Novel NRTTI MK-8591 Suppress HIV for At Least Seven Days - (07/26/17) New HIV Drugs, Aging, Life Expectancy - (07/26/17) Predictor factors associated with liver fibrosis and steatosis by transient elastography in HIV mono-infected patients under long-term combined antiretroviral therapy - (07/26/17) Safety, Tolerability, and Pharmacokinetics of Long-Acting Injectable Cabotegravir in Low-Risk HIV-uninfected Women and Men HPTN 077 - (07/26/17) New Nonnuke Doravirine Strong as Single-Tablet Regimen With TDF/3TC - Mark Mascolini - (07/26/17) HIV Viral Remission in Child with Perinatal HIV - (07/25/17) Single doses as low as 0.5 mg of the novel NRTTI MK-8591 suppress HIV for at least seven days - (07/25/17) Merck's Investigational NNRTI, Doravirine, Meets Primary Efficacy Endpoint of Non-Inferiority to Efavirenz, Both in Combination with Other Antiretroviral Agents, in Pivotal Phase 3 Trial for Treatment of HIV-1 Infection - (07/25/17) Dolutegravir-Lamivudine as initial therapy in HIV-1 infected, ARV-naïve patients: 96 week results of the PADDLE trial - (07/25/17) Fixed-Dose Combination of Doravirine/Lamivudine/TDF is Non-Inferior to Efavirenz/Emtricitabine/TDF in Treatment-Naïve Adults With HIV-1 Infection: Week 48 Results of the Phase 3 DRIVE-AHEAD Study - (07/25/17) Superior Efficacy of Dolutegravir (DTG) Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Compared With Lopinavir/Ritonavir (LPV/RTV) Plus 2 NRTIs in Second-Line Treatment: Interim Data From the DAWNING Study - (07/25/17) Efficacy and safety of switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxilfumarate regimens to the single-tablet regimen (STR) of darunavir/cobicistat/emtricitabine/tenofoviralafenamide(D/C/F/TAF) in virologicallysuppressed, HIV-1-infected adults through 24 weeks: EMERALD Study - (07/25/17) Metabolic syndrome and obesity are the cornerstones of liver fibrosis in HIV-monoinfected patients: results of the METAFIB study - (07/25/17) Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial - (07/24/17) Evaluation of lead HIV-1 vaccine regimen in APPROACH: Phase 1/2a study testing heterologous prime boost regimens using mosaic Ad26 and MVA vectors combined with Env protein - (07/24/17) Dual regimen with Dolutegravir and Lamivudine maintains virologic suppression even in heavily treatment experienced HIV-infected patients: 96 weeks results from maintenance DOLULAM study - (07/24/17) Raltegravir 1200 mg Once Daily Versus Raltegravir 400 mg Twice Daily, in Combination With Tenofovir Disoproxil Fumarate/Emtricitabine, in Previously Untreated HIV-1 Infection Through Week 96 - (07/24/17) Safety and Efficacy of Long-Acting CAB and RPV as Two Drug IM Maintenance Therapy: LATTE-2 Week 96 Results - (07/24/17) ANRS 146 - GeSIDA 7211 OPTIMAL Optimized Phase III Trial of Immuno-stimulation with Maraviroc, a CCR5 antagonist, combined with Anti Retroviral Therapy (cART) in advanced, Late diagnosed HIV-1 infected patients with an AIDS-defining event and/or CD4 counts > 200 cells/ mm3 - (07/24/17) Glecaprevir/Pibrentasvir Fixed-Dose Combination for 8 or 12 Weeks in Patients Co-Infected With HCV and HIV-1: A Sub-Analysis of the Phase 3 ENDURANCE-1 Study - (07/24/17) Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Co-infected with Hepatitis C Virus and Human Immunodeficiency Virus-1: The EXPEDITION-2 Study - (07/24/17) Darunavir/Ritonavir Plus 3TC Noninferior to Triple Therapy at 24 Weeks - ANDES Study - A Phase 4, Randomized, Open Label, Study of a Ritonavir-Boosted Darunavir in Fixed Dose Combination (FD-DRV/r) plus Lamivudine Versus FD-DRV/r plus Lamivudine/Tenofovir in Naïve HIV-1 Infected Subjects - Mark Mascolini - (07/23/17) Low Failure Rate With Switch to Integrase Inhibitor STR Despite Archived Mutations - Mark Mascolini - (07/23/17) Long-Acting 4/8-Week Cabotegravir/Rilpivirine Maintains Control at 96 Weeks - Mark Mascolini - (07/23/17) MK-8591 Protects 8 of 8 Macaques From Rectal SHIV 6 Days After Dosing - Mark Mascolini - (07/23/17) CD4 Count at ART Start Rising Across Globe, But Median Still Below 350 / 25% start at below 200 CD4 - Mark Mascolini - (07/23/17) Virologic Success Rate 90% at Week 24 With First-Line DTG/3TC in ACTG A5353: ACTG A5353: A pilot study of dolutegravir (DTG) + lamivudine (3TC) for initial treatment of HIV-1-infected participants with HIV-1 RNA <500,000 copies/ml - Mark Mascolini - (07/23/17) A Phase 3 Randomized Controlled Clinical Trial of Bictegravir in a Fixed Dose Combination, B/F/TAF, vs DTG/ABC/3TC in Treatment-Naïve Adults at Week 48 - (07/23/17) A Phase 3 Randomized Controlled Clinical Trial of Bictegravir in a Fixed Dose Combination, B/F/TAF, vs DTG/ABC/3TC in Treatment-Naïve Adults at Week 48 - (07/23/17) More and earlier cardiovascular events (CVE) and shorter overall survival (OS) in HIV-positive patients (HIV+) compared to the general population differ by sex - (07/23/17) Gilead Announces Phase 3 Results for Investigational Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for Treatment of HIV - (07/23/17) Weekly Oral MK-8591 Protects Male Rhesus Macaques against Repeated Low Dose Intrarectal Challenge with SHIV109CP3 - (07/23/17) Johnson & Johnson at IAS 2017: Latest Innovations from its Janssen Pharmaceutical Companies Include First In-Human Data for Investigational Preventive HIV-1 Vaccine and Phase 3 Pivotal Trial Results for Darunavir-Based, Single-Tablet Regimen - (07/23/17) The effects of diet and lifestyle interventions on insulin resistance in patients with nonalcoholic fatty liver disease: a systematic review - (07/22/17) Ending AIDS: myth or reality? New Infections Increase in Key Populations, UN Update - (07/23/17) A global survey of HIV-positive people's attitudes towards cure research - (07/23/17)